Log in

NASDAQ:MRSNMersana Therapeutics Stock Price, Forecast & News

$21.57
-1.02 (-4.52 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$21.27
Now: $21.57
$22.84
50-Day Range
$9.90
MA: $19.83
$23.40
52-Week Range
$1.32
Now: $21.57
$24.97
Volume680,300 shs
Average Volume1.14 million shs
Market Capitalization$1.44 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.82
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies. Its lead product candidate is XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer, non small cell lung cancer, and other orphan indications. Mersana Therapeutics, Inc. has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.
Read More
Mersana Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.37 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MRSN
CUSIPN/A
Phone617-498-0020

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$42.12 million
Book Value$1.64 per share

Profitability

Net Income$-28,210,000.00
Net Margins-6,099.64%

Miscellaneous

Employees86
Market Cap$1.44 billion
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive MRSN News and Ratings via Email

Sign-up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter.

Mersana Therapeutics (NASDAQ:MRSN) Frequently Asked Questions

How has Mersana Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Mersana Therapeutics' stock was trading at $6.46 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MRSN shares have increased by 233.9% and is now trading at $21.57. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Mersana Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Mersana Therapeutics.

When is Mersana Therapeutics' next earnings date?

Mersana Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Mersana Therapeutics.

How were Mersana Therapeutics' earnings last quarter?

Mersana Therapeutics Inc (NASDAQ:MRSN) posted its earnings results on Friday, May, 8th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.03. The business earned $0.01 million during the quarter, compared to analysts' expectations of $0.37 million. Mersana Therapeutics had a negative net margin of 6,099.64% and a negative return on equity of 78.18%. View Mersana Therapeutics' earnings history.

What price target have analysts set for MRSN?

5 analysts have issued 12 month price targets for Mersana Therapeutics' shares. Their forecasts range from $20.00 to $32.00. On average, they expect Mersana Therapeutics' share price to reach $24.75 in the next twelve months. This suggests a possible upside of 14.7% from the stock's current price. View analysts' price targets for Mersana Therapeutics.

Has Mersana Therapeutics been receiving favorable news coverage?

Media headlines about MRSN stock have been trending very negative on Sunday, InfoTrie reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Mersana Therapeutics earned a news sentiment score of -3.2 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about Mersana Therapeutics.

Who are some of Mersana Therapeutics' key competitors?

What other stocks do shareholders of Mersana Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mersana Therapeutics investors own include Crispr Therapeutics (CRSP), Sorrento Therapeutics (SRNE), Amarin (AMRN), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Marinus Pharmaceuticals (MRNS), ImmunoGen (IMGN), vTv Therapeutics (VTVT), Advanced Micro Devices (AMD) and Clovis Oncology (CLVS).

Who are Mersana Therapeutics' key executives?

Mersana Therapeutics' management team includes the following people:
  • Ms. Anna Protopapas, Pres, CEO & Director (Age 55)
  • Mr. David A. Spellman, Chief Financial Officer (Age 42)
  • Dr. Timothy B. Lowinger, Sr. VP & Chief Scientific Officer (Age 55)
  • Mr. Mikhail Papisov Ph.D., Co-Founder
  • Ms. Sarah Carmody, Exec. Director of Investor Relations & Corp. Communications

When did Mersana Therapeutics IPO?

(MRSN) raised $75 million in an initial public offering on Wednesday, June 28th 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Mersana Therapeutics' stock symbol?

Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN."

Who are Mersana Therapeutics' major shareholders?

Mersana Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include FNY Investment Advisers LLC (0.22%). Company insiders that own Mersana Therapeutics stock include Andrew A F Hack, Ashish Mandelia, Enterprise Associates 14 New, Lawrence M Alleva, Scott D Sandell and Timothy B Lowinger. View institutional ownership trends for Mersana Therapeutics.

Which institutional investors are buying Mersana Therapeutics stock?

MRSN stock was purchased by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC. Company insiders that have bought Mersana Therapeutics stock in the last two years include Andrew A F Hack, Enterprise Associates 14 New, and Lawrence M Alleva. View insider buying and selling activity for Mersana Therapeutics.

How do I buy shares of Mersana Therapeutics?

Shares of MRSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Mersana Therapeutics' stock price today?

One share of MRSN stock can currently be purchased for approximately $21.57.

How big of a company is Mersana Therapeutics?

Mersana Therapeutics has a market capitalization of $1.44 billion and generates $42.12 million in revenue each year. The company earns $-28,210,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Mersana Therapeutics employs 86 workers across the globe.

What is Mersana Therapeutics' official website?

The official website for Mersana Therapeutics is www.mersana.com.

How can I contact Mersana Therapeutics?

Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-498-0020 or via email at [email protected]

This page was last updated on 7/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.